Document is current
Any future updates will be listed below
-
Authors
Yavi, Mani https://orcid.org/0000-0001-8387-4720
Lee, Holim https://orcid.org/0000-0002-2185-4975
Henter, Ioline D. https://orcid.org/0000-0002-2379-2413
Park, Lawrence T. https://orcid.org/0000-0002-6570-686X
Zarate, Carlos A. Jr https://orcid.org/0000-0003-4442-7412
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (ZIAMH002857)
National Institute of Mental Health (ZIAMH002857)
National Institute of Mental Health (ZIAMH002857)
National Institute of Mental Health (ZIAMH002857)
National Institute of Mental Health (ZIAMH002857)
National Institutes of Health
- License Information
-
More Information
Article History
Received: 18 January 2022
Accepted: 25 March 2022
First Online: 15 April 2022
Declarations
:
: Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
